Yonsei University

About: Yonsei University is a education organization based out in Seoul, South Korea. It is known for research contribution in the topics: Population & Cancer. The organization has 50162 authors who have published 106172 publications receiving 2279044 citations. The organization is also known as: Yonsei.

The determinants of corporate liquidity: Theory and evidence

Abstract: We model the firm's decision to invest in liquid assets when external financing is costly. The optimal amount of liquidity is determined by a tradeoff between the low return earned on liquid assets and the benefit of minimizing the need for costly external financing. The model predicts that the optimal investment in liquidity is increasing in the cost of external financing, the variance of future cash flows, and the return on future investment opportunities, while it is decreasing in the return differential between the firm's physical assets and liquid assets. Empirical tests on a large panel of U.S. industrial firms support the model's predictions.

THE SINS SURVEY: SINFONI INTEGRAL FIELD SPECTROSCOPY OF z ∼ 2 STAR-FORMING GALAXIES*

Abstract: We present the Spectroscopic Imaging survey in the near-infrared (near-IR) with SINFONI (SINS) of high-redshift galaxies. With 80 objects observed and 63 detected in at least one rest-frame optical nebular emission line, mainly Hα, SINS represents the largest survey of spatially resolved gas kinematics, morphologies, and physical properties of star-forming galaxies at z ~ 1-3. We describe the selection of the targets, the observations, and the data reduction. We then focus on the "SINS Hα sample," consisting of 62 rest-UV/optically selected sources at 1.3 < z < 2.6 for which we targeted primarily the Hα and [N II] emission lines. Only ≈30% of this sample had previous near-IR spectroscopic observations. The galaxies were drawn from various imaging surveys with different photometric criteria; as a whole, the SINS Hα sample covers a reasonable representation of massive M_* ≳ 10^(10) M_☉ star-forming galaxies at z ≈ 1.5-2.5, with some bias toward bluer systems compared to pure K-selected samples due to the requirement of secure optical redshift. The sample spans 2 orders of magnitude in stellar mass and in absolute and specific star formation rates, with median values ≈3 × 10^(10) M_☉, ≈70 M_☉ yr^(–1), and ≈3 Gyr^(–1). The ionized gas distribution and kinematics are spatially resolved on scales ranging from ≈1.5 kpc for adaptive optics assisted observations to typically ≈4-5 kpc for seeing-limited data. The Hα morphologies tend to be irregular and/or clumpy. About one-third of the SINS Hα sample galaxies are rotation-dominated yet turbulent disks, another one-third comprises compact and velocity dispersion-dominated objects, and the remaining galaxies are clear interacting/merging systems; the fraction of rotation-dominated systems increases among the more massive part of the sample. The Hα luminosities and equivalent widths suggest on average roughly twice higher dust attenuation toward the H II regions relative to the bulk of the stars, and comparable current and past-averaged star formation rates.

The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level : results from the Global Burden of Disease Study 2015

Abstract: Importance Liver cancer is among the leading causes of cancer deaths globally. The most common causes for liver cancer include hepatitis B virus (HBV) and hepatitis C virus (HCV) infection and alcohol use. Objective To report results of the Global Burden of Disease (GBD) 2015 study on primary liver cancer incidence, mortality, and disability-adjusted life-years (DALYs) for 195 countries or territories from 1990 to 2015, and present global, regional, and national estimates on the burden of liver cancer attributable to HBV, HCV, alcohol, and an “other” group that encompasses residual causes. Design, Settings, and Participants Mortality was estimated using vital registration and cancer registry data in an ensemble modeling approach. Single-cause mortality estimates were adjusted for all-cause mortality. Incidence was derived from mortality estimates and the mortality-to-incidence ratio. Through a systematic literature review, data on the proportions of liver cancer due to HBV, HCV, alcohol, and other causes were identified. Years of life lost were calculated by multiplying each death by a standard life expectancy. Prevalence was estimated using mortality-to-incidence ratio as surrogate for survival. Total prevalence was divided into 4 sequelae that were multiplied by disability weights to derive years lived with disability (YLDs). DALYs were the sum of years of life lost and YLDs. Main Outcomes and Measures Liver cancer mortality, incidence, YLDs, years of life lost, DALYs by etiology, age, sex, country, and year. Results There were 854 000 incident cases of liver cancer and 810 000 deaths globally in 2015, contributing to 20 578 000 DALYs. Cases of incident liver cancer increased by 75% between 1990 and 2015, of which 47% can be explained by changing population age structures, 35% by population growth, and −8% to changing age-specific incidence rates. The male-to-female ratio for age-standardized liver cancer mortality was 2.8. Globally, HBV accounted for 265 000 liver cancer deaths (33%), alcohol for 245 000 (30%), HCV for 167 000 (21%), and other causes for 133 000 (16%) deaths, with substantial variation between countries in the underlying etiologies. Conclusions and Relevance Liver cancer is among the leading causes of cancer deaths in many countries. Causes of liver cancer differ widely among populations. Our results show that most cases of liver cancer can be prevented through vaccination, antiviral treatment, safe blood transfusion and injection practices, as well as interventions to reduce excessive alcohol use. In line with the Sustainable Development Goals, the identification and elimination of risk factors for liver cancer will be required to achieve a sustained reduction in liver cancer burden. The GBD study can be used to guide these prevention efforts.

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

Abstract: Here we studied cell-free plasma DNA (cfDNA) collected from subjects with advanced lung cancer whose tumors had developed resistance to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) AZD9291. We first performed next-generation sequencing of cfDNA from seven subjects and detected an acquired EGFR C797S mutation in one; expression of this mutant EGFR construct in a cell line rendered it resistant to AZD9291. We then performed droplet digital PCR on serial cfDNA specimens collected from 15 AZD9291-treated subjects. All were positive for the T790M mutation before treatment, but upon developing AZD9291 resistance three molecular subtypes emerged: six cases acquired the C797S mutation, five cases maintained the T790M mutation but did not acquire the C797S mutation and four cases lost the T790M mutation despite the presence of the underlying EGFR activating mutation. Our findings provide insight into the diversity of mechanisms through which tumors acquire resistance to AZD9291 and highlight the need for therapies that are able to overcome resistance mediated by the EGFR C797S mutation.